News Search

In Notes from the Lab, we spotlight the Giancotti lab and new research identifying factors that sustain prostate cancer cells that have become resistant to androgen receptor (AR) therapy.

"My role is to ... be more than just the connector in the community, but also the link between the clinical world and the community," says HICCC Community Advisory Board Member Dr. Ginny Mantello.

A new study led by Dr. Andrew Lassman addresses safety and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR)-tyrosine kinase inhibitor, for patients with recurrent glioblastomas.

The U.S. Preventative Services Task Force now recommends that colon cancer screening start at age 45, with increasing numbers of young people with colon cancer becoming a troubling trend.